No Data
No Data
JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Has Debt But No Earnings; Should You Worry?
Minsheng Securities: Performance differentiation in the second quarter of 2024 in the commercial retail sector, with sufficient performance resilience for overseas and beauty industry leaders.
Beauty and makeup 24H1 saw a slight increase, with e-commerce platforms returning to GMV logic, and top domestic beauty and makeup brands performing well.
Jiangsu Wu Zhong Medicine Development Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Jiangsu Wuzhong Pharmaceutical Development (600200.SH): net income in the first half of the year was 24.4546 million yuan, a year-on-year decrease of 10.75%.
On August 27, GeLongHui reported that Jiangsu Wuzhong (600200.SH) released its semi-annual report. In the first half of 2024, the company achieved revenue of 1.2 billion yuan, an increase of 105.8792 million yuan compared to the same period last year, an increase of 9.62%. It achieved a net income attributable to the owners of the parent company of 24.4546 million yuan, compared to 27.4006 million yuan in the same period last year, a decrease of 10.75% year-on-year.
JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Shareholder Returns Have Been Respectable, Earning 85% in 5 Years
No Data
No Data